Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Docetaxel in Advanced Non-Squamous NSCLC
NCT02780778Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02780778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780778.